Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Enveric Biosciences, Inc. (ENVB)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.8700+0.0100 (+0.35%)
At close: 03:59PM EST
2.9900 +0.13 (+4.55%)
After hours: 05:11PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.8600
Open2.7800
Bid2.8600 x 1000
Ask2.9100 x 1400
Day's Range2.7800 - 2.9550
52 Week Range1.5700 - 34.3500
Volume28,172
Avg. Volume46,048
Market Cap90.071M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.6740
Earnings DateMar 29, 2023 - Apr 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateApr 23, 2008
1y Target Est32.50
  • Business Wire

    Enveric Biosciences to Present at the 6th Annual Neuroscience Innovation Forum and Biotech Showcase during "J.P. Morgan Health Care Week 2023"

    CAMBRIDGE, Mass., December 21, 2022--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, announced today that the company will present at the 6th Annual Neuroscience Forum and the Biotech Showcase™. Both events will be held live and are scheduled to coincide with the 41st Annual J.P. Morgan Health Care Conference in San Francisco

  • Business Wire

    Enveric Biosciences Announces Confidential Submission of Registration Statement for the Spin-off of its Cannabinoid Business to Shareholders

    CAMBRIDGE, Mass., November 28, 2022--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced the confidential submission of a Form S-1 draft registration statement with the U.S. Securities and Exchange Commission (‘SEC’) for the spin-off its cannabinoid clinical development pipeline to a wholly-owned subsidiary, Akos

  • Business Wire

    Enveric Biosciences to Participate in A.G.P.’s Virtual Biotech Conference

    CAMBRIDGE, Mass., November 16, 2022--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced that Avani Kanubaddi, President & COO of Enveric Biosciences, will participate in A.G.P.’s Virtual Biotech Conference to be held from November 30, 2022 – December 1, 2022.

Advertisement
Advertisement